Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Care with Guselkumab in Crohn’s Disease
2025-524573-16-00Phase 4Authorised
- Sponsor
- i-GETAID
- Start
- Apr 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of guselkumab in Crohn's disease, sponsored by i-GETAID. Primary endpoint: Steroid free clinical remission with biomarker remission at week 48. Planned start Apr 2026; status: authorised.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2025-524573-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524573-16-00.